Background. A common strategy for preventing nosocomial MRSA transmission is reactive isolation after positive nares surveillance. However, nares screening has low sensitivity for MRSA carriage. In high-risk patients, some have considered non-nares screening or presumptive isolation without surveillance. We sought to model the economic implementation cost, from a hospital perspective, of strategies for high-risk admissions.
Methods. We modeled the economic impact of three body-site MRSA screening (nares, pharynx, and inguinal folds) and presumptive isolation for high-risk admissions from a hospital perspective. Projected costs and benefits were derived from the literature. We examined threshold values for 1) probability of MRSA carriage in an admitted patient and 2) impact of MRSA infection (in terms of increased length of stay) that would be cost-neutral (costs = benefits).
Results. In our baseline model, the costs of both screening and isolation and presumptive isolation exceeded savings generated by preventing MRSA infections. Nares screening and contact precautions prevented 0.6 infections (95% CR, 0.5-0.7) per 1,000 high-risk admissions, and yielded a net financial loss of $36,899 (95% CR, $31,525 to $42,690). Three body-site surveillance prevented 0.8 infections (95% CR, 0.7-0.9) per 1,000 high-risk admissions, but resulted in even greater higher financial loss $51,478 (95% CR, $45,566 to $57,821). Presumptive isolation prevented the most infections (1.0 infections; 95% CR, 0.9-1.1), but resulted in large financial losses $300,765 (95% CR, $296,155 to $304,835) of any model tested. Using optimistic estimates for the efficacy of isolation in terms of preventing new MRSA infections, three bodysite surveillance could be cost-neutral in targeted populations at risk for high-complexity infections, e.g., prosthetic joint infections or post-operative mediastinitis. Presumptive isolation was never cost-neutral.
Conclusion. Although multiple body site surveillance or presumptive isolation for high-risk patients could reduce nosocomial MRSA infections, the program's overall cost exceeds any savings generated from infections prevented. For an individual hospital, the cost of screening and isolation needs to weighed against other infection control interventions and patient safety efforts.
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